Study Protocol for Feasibility Randomized, Placebo-Controlled Trial of Efficacy of Midazolam as the Second-Line Treatment for Dyspnea in Patients with Advanced Cancer.

Authors

Satoru Miwa, Masanori Mori, Shunsuke Oyamada, Takuhiro Yamaguchi, Keisuke Ariyoshi, Yoshinobu Matsuda, Kozue Suzuki, Junichi Tasaki, Yutaka Hatano, Kaoru Nishijima, Sayo Aiki, Satoshi Hagimoto, Toshiyuki Kuriyama, Yuka Okuda, Shimon Tashiro, Yoshihisa Matsumoto, Hironobu Hashimoto, Takashi Kawaguchi, Hiroshi Ishiguro, Sadamoto Zenda, Hiromichi Matsuoka, David Hui, Tatsuya Morita, Takashi Yamaguchi

Published in

Palliative medicine reports. Volume 7. Pages 26892820261461866. Epub Jul 17, 2026.

Abstract

Dyspnea is one of the most distressing symptoms in patients with advanced cancer. Although systemic opioids are recommended as first-line pharmacologic treatment, 30-50% of patients do not achieve adequate relief. Midazolam is often used for persistent dyspnea despite opioid administration; however, robust evidence supporting its efficacy as a second-line treatment remains limited.
To evaluate the feasibility of a randomized controlled trial assessing the efficacy and safety of continuous subcutaneous midazolam infusion as second-line treatment for persistent dyspnea despite morphine administration in hospitalized patients with advanced cancer.
A protocol for a multicenter, randomized, double-blind, placebo-controlled feasibility trial (J-SUPPORT2201/JORTC-PAL22) is described. The trial is being conducted at nine sites in Japan.
Participants are hospitalized adult patients with advanced cancer who are not receiving active anticancer treatment and who experience dyspnea at rest (Integrated Palliative Care Outcome Scale dyspnea score ≥2) despite continuous morphine infusion.
Protocol treatment includes standardized morphine escalation plus continuous subcutaneous infusion of midazolam (9 or 6 mg/day for vulnerable patients) or placebo for 24 hours.
The primary endpoint is feasibility, defined as completion of protocol treatment at 24 hours. Secondary endpoints include dyspnea intensity, anxiety, rescue morphine use, communication, adverse events, and 30-day survival.
This feasibility trial will provide methodological insights and preliminary clinical data regarding midazolam as a second-line option for persistent dyspnea despite morphine infusion in patients with advanced cancer and help design future confirmatory trials.

PMID:
42539342
Bibliographic data and abstract were imported from PubMed on 01 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.